The Use of PDX1 DNA Methylation to Distinguish Two Subtypes of Pancreatic Neuroendocrine Neoplasms with Different Prognoses

Hendrik Ungefroren; Björn Konukiewitz; Ulrich F. Wellner; Jörg Schrader; Tobias Keck

doi:10.3390/cancers15010160

Cancers (Dec 2022)

The Use of PDX1 DNA Methylation to Distinguish Two Subtypes of Pancreatic Neuroendocrine Neoplasms with Different Prognoses

Hendrik Ungefroren,
Björn Konukiewitz,
Ulrich F. Wellner,
Jörg Schrader,
Tobias Keck

Affiliations

Hendrik Ungefroren: First Department of Medicine, University Hospital Schleswig-Holstein (UKSH), Campus Lübeck, 23538 Lübeck, Germany
Björn Konukiewitz: Institute of Pathology, University Hospital Schleswig-Holstein (UKSH), Campus Kiel, 23538 Lübeck, Germany
Ulrich F. Wellner: Department of Surgery, University Hospital Schleswig-Holstein (UKSH), Campus Lübeck, 23538 Lübeck, Germany
Jörg Schrader: First Department of Medicine, University Hospital Hamburg-Eppendorf, 20251 Hamburg, Germany
Tobias Keck: Department of Surgery, University Hospital Schleswig-Holstein (UKSH), Campus Lübeck, 23538 Lübeck, Germany

DOI: https://doi.org/10.3390/cancers15010160
Journal volume & issue: Vol. 15, no. 1
p. 160

Abstract

Read online

Pancreatic neuroendocrine neoplasms (pNENs) account for approximately 5% of all pancreatic tumors; thus, they constitute the second most common tumor type in the pancreas [...]

n/a

Published in Cancers

ISSN: 2072-6694 (Online)
Publisher: MDPI AG
Country of publisher: Switzerland
LCC subjects: Medicine: Internal medicine: Neoplasms. Tumors. Oncology. Including cancer and carcinogens
Website: https://www.mdpi.com/journal/cancers/

About the journal

Abstract

Keywords